NATICK, Mass., January 23, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

NEW ORLEANS — Medications in development would preserve muscle mass and augment fat loss when used in combination with glucagon-like peptide 1 (GLP-1 ... risk for muscle atrophy and weakness.

Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat obesity ... Analysis is ongoing to compare differences in weight loss, lean mass, and ...

over two times higher than the maximum dose of 1.0mg used in the combination approach. "Muscle wasting and lack of adherence are significant challenges for GLP-1s, and this initial data suggests ...

But weight loss doesn't discriminate between fat and muscle. Patients using GLP-1 drugs can experience rapid and substantial muscle loss, accounting for as much as 40% of their total weight loss.

Asked how this intervention might compare with drugs in development to mitigate muscle loss with GLP-1 RA therapy, Peralta-Reich said “while we are optimistic we are not applying the results of ...

Back to Healio NATIONAL HARBOR, Md. — GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about the long-term effects of these ...

In comparison ... study with less fat and more muscle than the ones in the semaglutide-only group. When the Wegovy stops, the weight gain restarts. Could a GLP-1 gene therapy change that?

BOSTON - People who use popular weight loss drugs may be at risk for muscle wasting. Glucagon-like peptide 1 (GLP-1) drugs, like Ozempic and Wegovy, are incredibly effective at helping overweight ...

“Reductions in lean mass and muscle wasting are significant unmet needs in the GLP-1 space, and our early data suggests that we may have a powerful tool in achieving more metabolically healthy ...